Hisamitsu Pharmaceutical Co. Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP X… Read more
Hisamitsu Pharmaceutical Co. Inc (HPX) - Total Liabilities
Latest total liabilities as of August 2024: €74.55 Billion EUR
Based on the latest financial reports, Hisamitsu Pharmaceutical Co. Inc (HPX) has total liabilities worth €74.55 Billion EUR as of August 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hisamitsu Pharmaceutical Co. Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Hisamitsu Pharmaceutical Co. Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hisamitsu Pharmaceutical Co. Inc Competitors by Total Liabilities
The table below lists competitors of Hisamitsu Pharmaceutical Co. Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dr Ing hcF Porsche AG
F:P911
|
Germany | €29.67 Billion |
|
Enka Insaat ve Sanayi A.S
OTCGREY:EKIVF
|
USA | $2.61 Billion |
|
Dave Inc
NASDAQ:DAVE
|
USA | $134.70 Million |
|
Hellenic Telec
LSE:0FIZ
|
UK | €3.45 Billion |
|
ComfortDelGro Corporation Limited
STU:VZ1
|
Germany | €2.89 Billion |
|
InnoDisk
TWO:5289
|
Taiwan | NT$3.49 Billion |
|
Grupa KĘTY SA
WAR:KTY
|
Poland | zł2.69 Billion |
|
Adamas Trust, Inc.
NASDAQ:ADAMG
|
USA | $11.00 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Hisamitsu Pharmaceutical Co. Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hisamitsu Pharmaceutical Co. Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hisamitsu Pharmaceutical Co. Inc (2014–2025)
The table below shows the annual total liabilities of Hisamitsu Pharmaceutical Co. Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-02-28 | €63.66 Billion | +3.18% |
| 2024-02-29 | €61.70 Billion | +11.15% |
| 2023-02-28 | €55.51 Billion | +15.71% |
| 2022-02-28 | €47.98 Billion | +4.17% |
| 2021-02-28 | €46.06 Billion | -18.72% |
| 2020-02-29 | €56.66 Billion | +14.80% |
| 2019-02-28 | €49.35 Billion | -9.76% |
| 2018-02-28 | €54.69 Billion | +10.22% |
| 2017-02-28 | €49.62 Billion | -15.70% |
| 2016-02-29 | €58.86 Billion | -7.14% |
| 2015-02-28 | €63.39 Billion | +14.12% |
| 2014-02-28 | €55.55 Billion | -- |